KURA NASDAQ
San Diego, CA 92121
US
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fulk Jennifer | A-Award | 450,000 | $12.52 | 2026-09-08 |
| Fulk Jennifer | 0 | — | 2026-09-08 | |
| WILSON TROY EDWARD | P-Purchase | 100,000 | $12.39 | 2026-08-24 |
| Powl Brian T. | S-Sale | 4,345 | $11.89 | 2026-08-21 |
| Bair Teresa Brophy | S-Sale | 31,487 | $12.63 | 2026-08-19 |